TSPAN33 is a novel marker of activated and malignant B cells

Clinical Immunology

Volumn 149, Issue 3 PB, 2013, Pages 388-399

  Luu, Van Phi ^a   Hevezi, Peter ^a   Vences Catalan, Felipe ^b   Maravillas Montero, José Luis ^a   White, Clayton Alexander ^a,c   Casali, Paolo ^a,c   Llorente, Luis ^d   Jakez Ocampo, Juan ^d   Lima, Guadalupe ^d   Vilches Cisneros, Natalia ^e   Flores Gutiérrez, Juan Pablo ^e   Santos Argumedo, Leopoldo ^b   Zlotnik, Albert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

B cells; Biomarker; Lupus erythematosus; Lymphoma; Rheumatoid arthritis; Tetraspanin 33

Indexed keywords

B CELL MATURATION ANTIGEN; B LYMPHOCYTE ANTIGEN; BIOLOGICAL MARKER; CD19 ANTIGEN; CD20 ANTIGEN; INTERLEUKIN 21; INTERLEUKIN 6; TETRASPANIN; TETRASPANIN 33; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RETRIEVAL; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; BURKITT LYMPHOMA; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY DISTAL TUBULE; KIDNEY MEDULLA; KIDNEY PROXIMAL TUBULE; LARGE CELL LYMPHOMA; LEUKEMIA CELL LINE; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SLEDAI; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84887188377     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.08.005     Document Type: Article

References (69)

1. Rothenberg E.V., Moore J.E., Yui M.A. Launching the T-cell-lineage developmental programme. Nat. Rev. Immunol. 2008, 8:9-21.
2. Hardy R.R., Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 2001, 19:595-621.
3. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 2010, 28:445-489.
4. Suda T., O'Garra A., MacNeil I., Fischer M., Bond M.W., Zlotnik A. Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. Cell. Immunol. 1990, 129:228-240.
5. Bouaziz J.D., Yanaba K., Tedder T.F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 2008, 224:201-214.
6. Katz S.I., Parker D., Turk J.L. B-cell suppression of delayed hypersensitivity reactions. Nature 1974, 251:550-551.
7. Korhonen R., Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol. 2010, 106:13-21.
8. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 2006, 6:859-866.
9. Lee J., Hever A., Willhite D., Zlotnik A., Hevezi P. Effects of RNA degradation on gene expression analysis of human postmortem tissues. FASEB J. 2005, 19:1356-1358.
10. Roth R.B., Hevezi P., Lee J., Willhite D., Lechner S.M., Foster A.C., Zlotnik A. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7:67-80.
11. Gerber P.A., Hevezi P.A., Buhren B.A., Martinez C., Schrumpf H., Gasis M., Grether-Beck S., Krutmann J., Homey B., Zlotnik A. Systematic identification and characterization of novel human skin-associated genes encoding membrane and secreted proteins. PLoS One 2013, e63949.
12. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997, 11:428-442.
13. van Spriel A.B., Puls K.L., Sofi M., Pouniotis D., Hochrein H., Orinska Z., Knobeloch K.P., Plebanski M., Wright M.D. A regulatory role for CD37 in T cell proliferation. J. Immunol. 2004, 172:2953-2961.
14. Heikens M.J., Cao T.M., Morita C., Dehart S.L., Tsai S. Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis. Blood 2007, 109:3244-3252.
15. Seita J., Sahoo D., Rossi D.J., Bhattacharya D., Serwold T., Inlay M.A., Ehrlich L.I., Fathman J.W., Dill D.L., Weissman I.L. Gene expression commons: an open platform for absolute gene expression profiling. PLoS One 2012, 7:e40321.
16. Xu Z., Fulop Z., Wu G., Pone E.J., Zhang J., Mai T., Thomas L.M., Al-Qahtani A., White C.A., Park S.R., Steinacker P., Li Z., Yates J., Herron B., Otto M., Zan H., Fu H., Casali P. 14-3-3 adaptor proteins recruit AID to 5'-AGCT-3'-rich switch regions for class switch recombination. Nat. Struct. Mol. Biol. 2010, 17:1124-1135.
17. Kim K.J., Kanellopoulos-Langevin C., Merwin R.M., Sachs D.H., Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 1979, 122:549-554.
18. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-1277.
19. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35:630-640.
20. Burkhardt A.M., Tai K.P., Flores-Guiterrez J.P., Vilches-Cisneros N., Kamdar K., Barbosa-Quintana O., Valle-Rios R., Hevezi P.A., Zuniga J., Selman M., Ouellette A.J., Zlotnik A. CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity. J. Immunol. 2012, 188:6399-6406.
21. Schaffer A., Cerutti A., Shah S., Zan H., Casali P. The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites. J. Immunol. 1999, 162:5327-5336.
22. Park S.R., Zan H., Pal Z., Zhang J., Al-Qahtani A., Pone E.J., Xu Z., Mai T., Casali P. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. Nat. Immunol. 2009, 10:540-550.
23. Maravillas-Montero J.L., Gillespie P.G., Patino-Lopez G., Shaw S., Santos-Argumedo L. Myosin 1c participates in B cell cytoskeleton rearrangements, is recruited to the immunologic synapse, and contributes to antigen presentation. J. Immunol. 2011, 187:3053-3063.
24. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., Kaslow R.A., Variakojis D., Bream J.H., Rinaldo C.R., Ambinder R.F., Martinez-Maza O. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1303-1314.
25. De Roos A.J., Mirick D.K., Edlefsen K.L., LaCroix A.Z., Kopecky K.J., Madeleine M.M., Magpantay L., Martinez-Maza O. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res. 2012, 72:4733-4743.
26. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984, 63:1424-1433.
27. Gurbuxani S., Anastasi J., Hyjek E. Diffuse large B-cell lymphoma-more than a diffuse collection of large B cells: an entity in search of a meaningful classification. Arch. Pathol. Lab. Med. 2009, 133:1121-1134.
28. McGowan P., Nelles N., Wimmer J., Williams D., Wen J., Li M., Ewton A., Curry C., Zu Y., Sheehan A., Chang C.C. Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. Am. J. Clin. Pathol. 2012, 137:665-670.
29. Nakamura N., Nakamine H., Tamaru J., Nakamura S., Yoshino T., Ohshima K., Abe M. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod. Pathol. 2002, 15:771-776.
30. Kuppers R. The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 2009, 9:15-27.
31. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117:26-38.
32. Nyman H., Jerkeman M., Karjalainen-Lindsberg M.L., Banham A.H., Leppa S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod. Pathol. 2009, 22:1094-1101.
33. Suzuki Y., Yoshida T., Wang G., Togano T., Miyamoto S., Miyazaki K., Iwabuchi K., Nakayama M., Horie R., Niitsu N., Sato Y., Nakamura N. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann. Hematol. 2012, 91:997-1005.
34. Dorner T., Giesecke C., Lipsky P.E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 2011, 13:243.
35. Spronk P.E., vd Gun B.T., Limburg P.C., Kallenberg C.G. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation. Clin. Exp. Immunol. 1993, 93:39-44.
36. Gottenberg J.E., Miceli-Richard C., Ducot B., Goupille P., Combe B., Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res. Ther. 2009, 11:R114.
37. Gottenberg J.E., Dayer J.M., Lukas C., Ducot B., Chiocchia G., Cantagrel A., Saraux A., Roux-Lombard P., Mariette X. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann. Rheum. Dis. 2012, 71:1243-1248.
38. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., Weyand C.M. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 2005, 115:3083-3092.
39. White C.A., Seth Hawkins J., Pone E.J., Yu E.S., Al-Qahtani A., Mai T., Zan H., Casali P. AID dysregulation in lupus-prone MRL/Fas(lpr/lpr) mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4. Autoimmunity 2011, 44:585-598.
40. Cohen P.L., Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 1991, 9:243-269.
41. Zan H., Zhang J., Ardeshna S., Xu Z., Park S.R., Casali P. Lupus-prone MRL/faslpr/lpr mice display increased AID expression and extensive DNA lesions, comprising deletions and insertions, in the immunoglobulin locus: concurrent upregulation of somatic hypermutation and class switch DNA recombination. Autoimmunity 2009, 42:89-103.
42. Liu J., Karypis G., Hippen K.L., Vegoe A.L., Ruiz P., Gilkeson G.S., Behrens T.W. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 2006, 7:156-168.
43. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999, 189:1639-1648.
44. Coquery C.M., Erickson L.D. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit. Rev. Immunol. 2012, 32:287-305.
45. Shaffer A.L., Lin K.I., Kuo T.C., Yu X., Hurt E.M., Rosenwald A., Giltnane J.M., Yang L., Zhao H., Calame K., Staudt L.M. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002, 17:51-62.
46. Jourdan M., Caraux A., De Vos J., Fiol G., Larroque M., Cognot C., Bret C., Duperray C., Hose D., Klein B. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009, 114:5173-5181.
47. Fairfax K.A., Kallies A., Nutt S.L., Tarlinton D.M. Plasma cell development: from B-cell subsets to long-term survival niches. Semin. Immunol. 2008, 20:49-58.
48. Soto H., Hevezi P., Roth R.B., Pahuja A., Alleva D., Acosta H.M., Martinez C., Ortega A., Lopez A., Araiza-Casillas R., Zlotnik A. Gene array analysis comparison between rat collagen-induced arthritis and human rheumatoid arthritis. Scand. J. Immunol. 2008, 68:43-57.
49. Silverman G.J., Carson D.A. Roles of B cells in rheumatoid arthritis. Arthritis Res. Ther. 2003, 5(Suppl. 4):S1-S6.
50. Martinez-Gamboa L., Brezinschek H.P., Burmester G.R., Dorner T. Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun. Rev. 2006, 5:437-442.
51. Bluml S., McKeever K., Ettinger R., Smolen J., Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res. Ther. 2013, 15(Suppl. 1):S4.
52. Vancsa A., Szabo Z., Szamosi S., Bodnar N., Vegh E., Gergely L., Szucs G., Szanto S., Szekanecz Z. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. J. Rheumatol. 2013, 40:565-571.
53. LeBien T.W., Tedder T.F. B lymphocytes: how they develop and function. Blood 2008, 112:1570-1580.
54. Naito Y., Takematsu H., Koyama S., Miyake S., Yamamoto H., Fujinawa R., Sugai M., Okuno Y., Tsujimoto G., Yamaji T., Hashimoto Y., Itohara S., Kawasaki T., Suzuki A., Kozutsumi Y. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol. Cell. Biol. 2007, 27:3008-3022.
55. Goteri G., Lucarini G., Zizzi A., Costagliola A., Giantomassi F., Stramazzotti D., Rubini C., Leoni P. Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas. Diagn. Pathol. 2011, 6:97.
56. Erlanson M., Gronlund E., Lofvenberg E., Roos G., Lindh J. Expression of activation markers CD23 and CD69 in B-cell non-Hodgkin's lymphoma. Eur. J. Haematol. 1998, 60:125-132.
57. Gregersen J.W., Jayne D.R. B-cell depletion in the treatment of lupus nephritis. Nat. Rev. Nephrol. 2012, 8:505-514.
58. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(Suppl. 5):v3-v11.
59. Cornec D., Devauchelle-Pensec V., Tobon G.J., Pers J.O., Jousse-Joulin S., Saraux A. B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J. Autoimmun. 2012, 39:161-167.
60. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22:7359-7368.
61. Rehnberg M., Amu S., Tarkowski A., Bokarewa M.I., Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 2009, 11:R123.
62. Haeuw J.F., Goetsch L., Bailly C., Corvaia N. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem. Soc. Trans. 2011, 39:553-558.
63. Sawada K., Hirokawa M., Fujishima N. Diagnosis and management of acquired pure red cell aplasia. Hematol. Oncol. Clin North Am. 2009, 23:249-259.
64. Haraldsson B., Nystrom J., Deen W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 2008, 88:451-487.
65. Surfus J.E., Hank J.A., Oosterwijk E., Welt S., Lindstrom M.J., Albertini M.R., Schiller J.H., Sondel P.M. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 1996, 19:184-191.
66. van Spriel A.B. Tetraspanins in the humoral immune response. Biochem. Soc. Trans. 2011, 39:512-517.
67. Mattila P.K., Feest C., Depoil D., Treanor B., Montaner B., Otipoby K.L., Carter R., Justement L.B., Bruckbauer A., Batista F.D. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity 2013, 38:461-474.
68. van Spriel A.B., de Keijzer S., van der Schaaf A., Gartlan K.H., Sofi M., Light A., Linssen P.C., Boezeman J.B., Zuidscherwoude M., Reinieren-Beeren I., Cambi A., Mackay F., Tarlinton D.M., Figdor C.G., Wright M.D. The tetraspanin CD37 orchestrates the alpha(4)beta(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci. Signal. 2012, 5:ra82.
69. Petersen S.H., Odintsova E., Haigh T.A., Rickinson A.B., Taylor G.S., Berditchevski F. The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur. J. Immunol. 2011, 41:2556-2561.